🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  2. Tibsovo 250 mg film-coated tablets

    The George Institute

    ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  3. Ticagrelor 90 mg

    AstraZeneca

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  4. Ticagrelor 90 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  5. Tildrakizumab Placebo Solution for Injection, TILDRAKIZUMAB

    Lacuna Pharma Pty Ltd

    Moderate to Severe Genital Psoriasis

    phase 3 small molecule active

    1 trial

  6. Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab

    Lacuna Pharma Pty Ltd

    Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis

    phase 3 small molecule active

    1 trial

  7. Timolol vehicle, Bimatoprost SR sham applicator, Timolol, Bimatoprost SR, Bimatoprost SR

    AbbVie Deutschland GmbH & Co. KG

    Ocular hypertension, Open-angle glaucoma

    phase 3 small molecule active

    1 trial

  8. Tinidazole oral microneedle patch

    The First People's Hospital of Lianyungang

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  9. Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  11. Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  12. Tirzepatide

    Eli Lilly and Company

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  13. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  14. Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. Tissue Plasminogen Activator

    Chinese University of Hong Kong

    Pleural Infection

    phase 3 small molecule active

    1 trial

  16. Tobacco Use Cessation

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 3 other completed

    1 trial

  17. Tobacco Use Disorder

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 3 other completed

    1 trial

  18. Tobevibart

    Vir Biotechnology

    Viral Hepatitis

    phase 3 small molecule active

    3 trials

  19. Tobramycin Injection

    United Therapeutics Europe Ltd

    Wound Infection

    phase 3 small molecule active

    1 trial

  20. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  21. Tofersen

    Biogen

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  22. Tofersen

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  23. Tofersen

    IONIS PHARMACEUTICALS INC

    ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

    phase 3 small molecule completed

    1 trial

  24. Topical Beremagene Geperpavec

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources